221 related articles for article (PubMed ID: 19246127)
1. [Atazanavir-induced nephrolithiasis].
Valencia ME; Moreno V
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
[No Abstract] [Full Text] [Related]
2. Drug interactions. Kaletra and atazanavir.
TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
[No Abstract] [Full Text] [Related]
3. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Bayonne Kombo ES; Gathse A
Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
[No Abstract] [Full Text] [Related]
4. A king in the CASTLE? Optimum initial HIV protease inhibitor.
Torti C; Frank I
Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
[No Abstract] [Full Text] [Related]
5. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Bongiovanni M; Chiesa E; Monforte Ad; Bini T
Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
[No Abstract] [Full Text] [Related]
6. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Chan-Tack KM; Truffa MM; Struble KA; Birnkrant DB
AIDS; 2007 May; 21(9):1215-8. PubMed ID: 17502736
[TBL] [Abstract][Full Text] [Related]
8. [New treatment options for HIV-infected patients].
Wehr A
Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Ondounda M; Tanon A; Ehui E; Ouattara I; Kassi A; Aba YT; Aoussi EF; Kakou AR; Eholié SP; Bissagnene E; Kadio A
Med Mal Infect; 2011 Feb; 41(2):105-7. PubMed ID: 20832214
[No Abstract] [Full Text] [Related]
11. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
12. The importance of sequencing in treatment options.
Berger DS
Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
[No Abstract] [Full Text] [Related]
13. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
14. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir in children.
Prescrire Int; 2011; 20(118):177. PubMed ID: 21751749
[No Abstract] [Full Text] [Related]
17. Kidney damage reported in some tenofovir users.
TreatmentUpdate; 2003; 15(2):6-7. PubMed ID: 12693362
[No Abstract] [Full Text] [Related]
18. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Buchacz K; Young B; Baker RK; Moorman A; Chmiel JS; Wood KC; Brooks JT
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):626-8. PubMed ID: 17133215
[No Abstract] [Full Text] [Related]
19. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
